These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36284264)

  • 21. CRISPR-Cas-Docker: web-based in silico docking and machine learning-based classification of crRNAs with Cas proteins.
    Park HM; Won J; Park Y; Anzaku ET; Vankerschaver J; Van Messem A; De Neve W; Shim H
    BMC Bioinformatics; 2023 Apr; 24(1):167. PubMed ID: 37098485
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Application of CRISPR-Mediated Gene Editing for Crop Improvement.
    Negi C; Vasistha NK; Singh D; Vyas P; Dhaliwal HS
    Mol Biotechnol; 2022 Nov; 64(11):1198-1217. PubMed ID: 35672603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exploiting endogenous CRISPR-Cas system for multiplex genome editing in Clostridium tyrobutyricum and engineer the strain for high-level butanol production.
    Zhang J; Zong W; Hong W; Zhang ZT; Wang Y
    Metab Eng; 2018 May; 47():49-59. PubMed ID: 29530750
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent advances in CRISPR technologies for genome editing.
    Song M; Koo T
    Arch Pharm Res; 2021 Jun; 44(6):537-552. PubMed ID: 34164771
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The CRISPR-Cas Mechanism for Adaptive Immunity and Alternate Bacterial Functions Fuels Diverse Biotechnologies.
    Newsom S; Parameshwaran HP; Martin L; Rajan R
    Front Cell Infect Microbiol; 2020; 10():619763. PubMed ID: 33585286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Machine learning predicts new anti-CRISPR proteins.
    Eitzinger S; Asif A; Watters KE; Iavarone AT; Knott GJ; Doudna JA; Minhas FUAA
    Nucleic Acids Res; 2020 May; 48(9):4698-4708. PubMed ID: 32286628
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization and applications of Type I CRISPR-Cas systems.
    Hidalgo-Cantabrana C; Barrangou R
    Biochem Soc Trans; 2020 Feb; 48(1):15-23. PubMed ID: 31922192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic and diagnostic relevance of Crispr technology.
    El Ouar I; Djekoun A
    Biomed Pharmacother; 2021 Jun; 138():111487. PubMed ID: 33774312
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Precision genome editing in plants: state-of-the-art in CRISPR/Cas9-based genome engineering.
    Wada N; Ueta R; Osakabe Y; Osakabe K
    BMC Plant Biol; 2020 May; 20(1):234. PubMed ID: 32450802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can genetic engineering-based methods for gene function identification be eclipsed by genome editing in plants? A comparison of methodologies.
    Amritha PP; Shah JM
    Mol Genet Genomics; 2021 May; 296(3):485-500. PubMed ID: 33751237
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent advances in CRISPR/Cas9 mediated genome editing in Bacillus subtilis.
    Hong KQ; Liu DY; Chen T; Wang ZW
    World J Microbiol Biotechnol; 2018 Sep; 34(10):153. PubMed ID: 30269229
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CAMERS-B: CRISPR/Cpf1 assisted multiple-genes editing and regulation system for Bacillus subtilis.
    Wu Y; Liu Y; Lv X; Li J; Du G; Liu L
    Biotechnol Bioeng; 2020 Jun; 117(6):1817-1825. PubMed ID: 32129468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CRISPR/Cas-based tools for the targeted control of plant viruses.
    Robertson G; Burger J; Campa M
    Mol Plant Pathol; 2022 Nov; 23(11):1701-1718. PubMed ID: 35920132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Class 2 CRISPR-Cas RNA-guided endonucleases: Swiss Army knives of genome editing.
    Stella S; Alcón P; Montoya G
    Nat Struct Mol Biol; 2017 Nov; 24(11):882-892. PubMed ID: 29035385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expanding the plant genome editing toolbox with recently developed CRISPR-Cas systems.
    Wada N; Osakabe K; Osakabe Y
    Plant Physiol; 2022 Mar; 188(4):1825-1837. PubMed ID: 35099553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Harnessing the native type I-B CRISPR-Cas for genome editing in a polyploid archaeon.
    Cheng F; Gong L; Zhao D; Yang H; Zhou J; Li M; Xiang H
    J Genet Genomics; 2017 Nov; 44(11):541-548. PubMed ID: 29169919
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CRISPR/Cas: a Nobel Prize award-winning precise genome editing technology for gene therapy and crop improvement.
    Li C; Brant E; Budak H; Zhang B
    J Zhejiang Univ Sci B; 2021 Apr; 22(4):253-284. PubMed ID: 33835761
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
    Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B
    J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PeNGaRoo, a combined gradient boosting and ensemble learning framework for predicting non-classical secreted proteins.
    Zhang Y; Yu S; Xie R; Li J; Leier A; Marquez-Lago TT; Akutsu T; Smith AI; Ge Z; Wang J; Lithgow T; Song J
    Bioinformatics; 2020 Feb; 36(3):704-712. PubMed ID: 31393553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Challenges of in vitro genome editing with CRISPR/Cas9 and possible solutions: A review.
    Ebrahimi V; Hashemi A
    Gene; 2020 Aug; 753():144813. PubMed ID: 32470504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.